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The aim of this pilot study was to examine the relationship between clinical response, adverse 
effects, sertraline (SERT) plasma concentrations and the genetic polymorphism of the 
serotonin transporter gene-linked polymorphic region (5HTTLPR) in 2 ethnic patient groups. 
The study involved 45 patients in a clinical trial who received a fixed dose regimen of 50 mg 
SERT for one week, then a variable-dose regimen for a further 6 weeks for major depressive 
disorder. At weeks 1 and 6, the following assessments were completed: Hamilton Depression 
Rating Scale (HDRS), Clinical Global Impression (CGI), drug adverse reaction scale and 
measurement of plasma SERT levels. Genomic analysis for the long and short allele variants 
of the 5HTTLPR polymorphism was also carried out. Caucasian subjects had a higher rate of 
l/l genotype while Chinese subjects had higher frequencies of l/s and s/s genotypes. 
Comparison of the subjects with the 5HTTLPR s/s genotype and those with the l/l and l/s 
genotypes found no significant differences in the HDRS scores, CGI scores, response rates, 
adverse effects and SERT plasma concentrations at week 6. 
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